Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT05700097

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05700097
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05700097. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-30 (actual); primary completion 2023-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
Condition
Acute Ischemic Stroke
Intervention (Drug)
Dengzhanxixin Injection
Intervention (Drug)
Placebo injection
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05700097
Content hash
782c41b385fa6be8dad71a1d78668f6bd11843f9f509893326a87aaf32570ff6